[February 10, 2014] |
|
WallStAnalyst.com: Generic Drug Makers Focus on Expansion into Biosimilars; US Stocks Edge Higher With Positive Consumer News
NEW YORK --(Business Wire)--
Wall St. Analyst (www.wallstanalyst.com)
has announced its comprehensive market summary that analyzes the most
relevant news, events, and economic releases. This edition of the
newsletter provides an insight into why the US stock market witnessed a
rebound during the week ended 7th February 2014 after
positive news relating to consumer credits released by the Fed. The
newsletter also throws the spotlight on how giant generic drug makers
are focusing their R&D efforts and investments on biosimilars as part of
their growth strategy to effectively compete with smaller companies in
the emerging nations.
Major Stock Indices Rise After the Fed's Consumer Credit Report The
Consumer Credit report for December released by the Federal Reserve
shows that consumer credit has increased. This brings into sharp focus
the debate as to whether the recovery of the US economy is for real or
just a blip on an otherwise dull outlook being portrayed by other key
economic indicators. As a result, the major stock indices rose during
the week, recording their first gain over the past four wees, after
being battered by weak labor market data as well as harsh weather
conditions. More details about the consumer sentiments in the US economy
is available at
http://wallstanalyst.com/research-desk/market-monitoring/1209-market-monitoring-week-ended-7-february-2014
Major Drug Makers Eye a Slice of Booming Biosimilars Market WallStAnalyst.com
analyses how the major generics drug makers are focusing on expansion
into the biosimilars market, which is seen to have huge potential over
the next few years. This is mainly because many blockbuster drugs are
expected to go off patent during the second half of 2014. Biosimilars
are currently witnessing high growth as they are relatively cheaper to
make and just as effective as their biopharmaceutical counterparts.
However, drug companies will have to tackle EU pricing pressure and
compete with popular branded products to gain a firm foothold in this
market. More details about growth prospects of the biosimilars market is
available at
http://wallstanalyst.com/blog/entry/giant-generic-drug-maker-teva-gets-new-seasoned-captain-on-board
Focus Concepts, Sectors, and Companies Verisign LinkedIn (News - Alert) Cigna
Corp. Noble Energy Netflix Expedia TripAdvisor Inc. Priceline.com
Inc. Flir Systems Inc. Wyndham Worldwide Apollo Global
Management Moody's Corp. Beam Inc. Western Union LabCorp Thomson (News - Alert)
Reuters
For more information visit www.wallstanalyst.com
[ Back To TMCnet.com's Homepage ]
|